+Search query
-Structure paper
Title | Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants. |
---|---|
Journal, issue, pages | Nat Commun, Vol. 14, Issue 1, Page 4198, Year 2023 |
Publish date | Jul 14, 2023 |
Authors | Saya Moriyama / Yuki Anraku / Shunta Taminishi / Yu Adachi / Daisuke Kuroda / Shunsuke Kita / Yusuke Higuchi / Yuhei Kirita / Ryutaro Kotaki / Keisuke Tonouchi / Kohei Yumoto / Tateki Suzuki / Taiyou Someya / Hideo Fukuhara / Yudai Kuroda / Tsukasa Yamamoto / Taishi Onodera / Shuetsu Fukushi / Ken Maeda / Fukumi Nakamura-Uchiyama / Takao Hashiguchi / Atsushi Hoshino / Katsumi Maenaka / Yoshimasa Takahashi / |
PubMed Abstract | SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS) antibodies that exist in diverse individuals as public antibody clones. We rationally selected RBS antibodies ...SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS) antibodies that exist in diverse individuals as public antibody clones. We rationally selected RBS antibodies resilient to mutations in emerging Omicron subvariants. Y489 was identified as a site of virus vulnerability and a common footprint of broadly neutralizing antibodies against the subvariants. Multiple Y489-binding antibodies were encoded by public clonotypes and additionally recognized F486, potentially accounting for the emergence of Omicron subvariants harboring the F486V mutation. However, a subclass of antibodies broadly neutralized BA.4/BA.5 variants via hydrophobic binding sites of rare clonotypes along with high mutation-resilience under escape mutation screening. A computationally designed antibody based on one of the Y489-binding antibodies, NIV-10/FD03, was able to bind XBB with any 486 mutation and neutralized XBB.1.5. The structural basis for the mutation-resilience of this Y489-binding antibody group may provide important insights into the design of therapeutics resistant to viral escape. |
External links | Nat Commun / PubMed:37452031 / PubMed Central |
Methods | EM (single particle) / X-ray diffraction |
Resolution | 2.2 - 4.2 Å |
Structure data | EMDB-33820: SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 focused on RBD and NIV-8 interface EMDB-33821: SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 1) EMDB-33822, PDB-7yh7: EMDB-33823: SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 focused on RBD and NIV-10 interface EMDB-33824: SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 1) EMDB-33825: SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 2) EMDB-33826: SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 3) EMDB-33827: SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 focused on RBD and NIV-13 interface EMDB-33828: SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 1) EMDB-33829: SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 2) EMDB-33830: SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 3) EMDB-34741, PDB-8hgl: EMDB-34742: SARS-CoV-2 spike in complex with neutralizing antibody NIV-11 focused on RBD and NIV-11 interface PDB-8hes: |
Chemicals | ChemComp-NAG: ChemComp-HOH: |
Source |
|
Keywords | VIRAL PROTEIN/IMMUNE SYSTEM / Complex / VIRAL PROTEIN / VIRAL PROTEIN-IMMUNE SYSTEM complex / virus / SARS-CoV-2 / RBD / spike / antibody / IgG / neutralizing antibody |